

Literatur

1. Argiolas A, Melis MR. The neurophysiology of the sexual cycle. *J Endocrinol Invest* 2003; 26(3 Suppl): 20–2.
2. Arzneimittelkommission der deutschen Ärzteschaft. Hypersexualität unter Aripiprazol (Abilify®). *Deutsches Ärzteblatt* 2006; 103(51–52): A3518.
3. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. *Hum Psychopharmacol Clin Exp* 2008; 23: 201–9.
4. Dossenbach M et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. *Int J Neuropsychopharmacol* 2005; 8(2): 195–201.
5. Freeman B, Levy W. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. *J Sychiatric Practice* 2007; 13(2): 120–4.
6. Frei A. Induktion paraphiler Handlungen als unerwünschte Wirkung der Neueinstellung auf Aripiprazol? *Schweizer Archiv für Neur und Psych* 2010; 161(2): 69–71.
7. Jenssens L et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study. *BMC Psychiatry* 2006; 8: 95.
8. Kelly DL, Conley R. Sexuality and schizophrenia: a review. *Schizophr Bull* 2000; 30(4): 767–79.
9. Macdonald et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. *BJP* 2003; 182: 50–6.
10. Meston CM, Frohlich PF. The neurobiology of sexual function. *Arch Gen Psychiatry* 2000; 57(11): 1012–30.
11. Mir A et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. *J Psychopharmacol* 2008; 22(3): 244–53.
12. Schlachetzki JCM, Langosch JM. Aripiprazol induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? *J Clin Psychopharmacology* 2008; 28(5): 567–8.
13. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. *Arch Neurol* 2007; 64(8): 1089–96.
14. Weydt P et al. Hypogonadism and gynecomastia with duloxetine. *Pharmacopsychiatry* 2011 Feb. 4; Epub ahead of print.
15. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. *Expert Opin Investig Drugs* 2007; 16(6): 771–5.